STTR Phase I: Steroid-eluting thread for the treatment of rhinitis

STTR 第一期：治疗鼻炎的类固醇洗脱线

• 批准号: 2305502
• 负责人: Cecil Lewis
• 金额: $ 25.5万
• 依托单位: SIMPLYBREATHE L.L.C.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-15 至 2024-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2305502&HistoricalAwards=false
• 关键词: STTR; Phase; Steroid; eluting; thread

The broader impact/commercial potential of this this Small Business Technology Transfer (STTR) Phase I project is a novel, minimally invasive, surgical option for reducing complications and improving outcomes for rhinitis patients. A bioabsorbable, steroid-eluting suture and surgical implant procedure will be developed to improve outcomes for 6 million patients suffering from rhinitis under the care of otolaryngologists, or ear, nose and throat specialists. The proposed suture system and surgical suite implant procedure enables a temporary therapy that replaces the need for current chronic, daily, topical sprays and/or long-term immunotherapy with a single in-office visit. The bioabsorbable, drug-eluting platform also provides potential extensibility for eluting other medications including antibiotic and antifungal therapies. This Small Business Technology Transfer Phase I project aims to deliver a prototype steroid-eluting dissolvable thread with an introducing surgical tool. The project is comprised of several steps including the formulation of dissolvable polymers, and prototyping using Hot Melt Extrusion (HME). This effort will advance the platform design and development of optimized drug-elution thread for use in the nasal cavity. The system will be designed using the preferred steroid of mometasone furoate and characterized for drug elution properties in a preclinical animal model.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业技术转让（STTR）I期项目的更广泛的影响/商业潜力是一种新型的微创手术选择，可减少并发症并改善鼻炎患者的结局。将开发一种生物可吸收、类固醇洗脱缝线和外科植入手术，以改善600万名鼻炎患者在耳鼻喉科医生或耳鼻喉科专家护理下的预后。申报的缝线系统和手术室植入程序能够实现临时治疗，通过单次门诊访视取代当前慢性、每日、局部喷雾和/或长期免疫治疗的需求。生物可吸收的药物洗脱平台还为洗脱其他药物（包括抗生素和抗真菌治疗）提供了潜在的可扩展性。这个小企业技术转让第一阶段项目的目的是提供一个原型类固醇洗脱可溶解的线程与介绍手术工具。该项目由几个步骤组成，包括可溶性聚合物的配方和使用热熔挤出（HME）的原型制作。这一努力将推进用于鼻腔的优化药物洗脱线的平台设计和开发。该系统的设计将使用首选的类固醇莫米松糠酸盐和药物洗脱特性的特点在临床前的动物模型。这个奖项反映了NSF的法定使命，并已被认为是值得通过使用基金会的智力价值和更广泛的影响审查标准进行评估的支持。